Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus

Review (27 RCTs: n= 4186) found pioglitazone reduced or delayed development of type 2 diabetes mellitus in people at increased risk vs placebo (low‐certainty evidence) and vs no intervention (moderate‐certainty evidence) but unclear whether effect is sustained once discontinued.

Cochrane Database of Systematic Reviews